Pro00113953_KEZAR Study A Randomized, Double-blind, Placebo-controlled, Phase 2a Study with Open-label Extension to Evaluate the Safety and Efficacy of Zetomipzomib (KZR-616) in Patients with Autoimmune Hepatitis